TY - JOUR
T1 - Cardiopulmonary Bypass Priming Practices and Blood Product Availability in Neonatal Cardiac Surgery
T2 - A European Survey
AU - EACTAIC Paediatric & Congenital Subspecialty Committee and Haemostasis and Transfusion Subspecialty Committee
AU - Paediatric & Congenital Subcommittee Survey Group
AU - Meier, Sascha
AU - Kousi, Theofili
AU - Romlin, Birgitta
AU - Haxhiademi, Dorela
AU - Lance, Marcus
AU - Aloisio, Tommaso
AU - Anvelt, Eneli
AU - Base, Eva
AU - Correia, Mariana
AU - von Dossow, Vera
AU - Erdoes, Gabor
AU - Friess, Jan Oliver
AU - Grabert, Josefin
AU - Gräfe, Katharina
AU - Humbert, Till
AU - Isgro, Giuseppe
AU - Janai, Aniruddha
AU - Khalil, Nadeen
AU - Kleine-Brüggeney, Maren
AU - van der Maaten, Joost
AU - Momeni, Mona
AU - Okkerse, Pieter
AU - Rex, Steffen
AU - Savluk, Ömer
AU - Schindler, Ehrenfried
AU - Stupnik, Spela
AU - Suliman, Mohamed
AU - Szedlak, Peter
AU - Szekely, Andrea
AU - Szekely, Edgar
AU - Velten, Markus
AU - Westcott, Georgina
N1 - Publisher Copyright:
© 2026 The Author(s)
PY - 2026
Y1 - 2026
N2 - Neonatal cardiac surgery requires cardiopulmonary bypass (CPB) strategies that minimize hemodilution while maintaining adequate oxygen delivery and hemostatic balance. Despite increasing emphasis on patient blood management (PBM), contemporary CPB priming and perioperative hemostasis practices across European neonatal cardiac surgery programs remain poorly characterized. This prospective, 26-item, web-based cross-sectional survey was designed to evaluate current practices in CPB priming, availability of blood products, and perioperative coagulation management strategies in neonatal cardiac surgery across Europe. The participants included anesthesiologists, congenital cardiac surgeons, and perfusionists from active neonatal cardiac surgery programs. A 26-item survey was distributed to 122 identified European neonatal cardiac surgery centers; 71 centers from 32 countries responded (58% response rate). Three main CPB machine platforms and four oxygenator types were reported. Priming volumes varied substantially across centers, ranging from 75 mL to 450 mL. Packed red blood cells were incorporated into the CPB prime in 58 centers (82%), while plasma products were used in 37 centers (52%). Coagulation factor concentrates were available in nearly half of the responding centers, and 64% reported that their use did not require hematology approval. Point-of-care coagulation testing was used to guide intraoperative hemostasis management in 86% of centers, although device availability and turnaround times varied widely. These results provide a contemporary snapshot and highlight substantial heterogeneity across European neonatal cardiac surgery programs in CPB priming strategies, blood product availability, and perioperative hemostasis management. While many centers have adopted point-of-care-guided PBM approaches and targeted factor replacement strategies, considerable variability persists in circuit configuration, priming volume, and transfusion resources. These findings highlight opportunities for collaborative research and for developing consensus-driven PBM frameworks to optimize neonatal CPB and perioperative hemostasis management.
AB - Neonatal cardiac surgery requires cardiopulmonary bypass (CPB) strategies that minimize hemodilution while maintaining adequate oxygen delivery and hemostatic balance. Despite increasing emphasis on patient blood management (PBM), contemporary CPB priming and perioperative hemostasis practices across European neonatal cardiac surgery programs remain poorly characterized. This prospective, 26-item, web-based cross-sectional survey was designed to evaluate current practices in CPB priming, availability of blood products, and perioperative coagulation management strategies in neonatal cardiac surgery across Europe. The participants included anesthesiologists, congenital cardiac surgeons, and perfusionists from active neonatal cardiac surgery programs. A 26-item survey was distributed to 122 identified European neonatal cardiac surgery centers; 71 centers from 32 countries responded (58% response rate). Three main CPB machine platforms and four oxygenator types were reported. Priming volumes varied substantially across centers, ranging from 75 mL to 450 mL. Packed red blood cells were incorporated into the CPB prime in 58 centers (82%), while plasma products were used in 37 centers (52%). Coagulation factor concentrates were available in nearly half of the responding centers, and 64% reported that their use did not require hematology approval. Point-of-care coagulation testing was used to guide intraoperative hemostasis management in 86% of centers, although device availability and turnaround times varied widely. These results provide a contemporary snapshot and highlight substantial heterogeneity across European neonatal cardiac surgery programs in CPB priming strategies, blood product availability, and perioperative hemostasis management. While many centers have adopted point-of-care-guided PBM approaches and targeted factor replacement strategies, considerable variability persists in circuit configuration, priming volume, and transfusion resources. These findings highlight opportunities for collaborative research and for developing consensus-driven PBM frameworks to optimize neonatal CPB and perioperative hemostasis management.
KW - anesthesia
KW - blood products
KW - cardiac surgery
KW - cardiopulmonary bypass
KW - neonatal
KW - patient blood management
UR - https://www.scopus.com/pages/publications/105047417532
U2 - 10.1053/j.jvca.2026.06.045
DO - 10.1053/j.jvca.2026.06.045
M3 - Article
C2 - 42575775
AN - SCOPUS:105047417532
SN - 1053-0770
JO - Journal of Cardiothoracic and Vascular Anesthesia
JF - Journal of Cardiothoracic and Vascular Anesthesia
ER -